TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02468167

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Balloon-occluded retrograde transvenous obliteration
Description: Balloon-occluded retrograde transvenous obliteration

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic cyanoacrylate injection
Description: Endoscopic cyanoacrylate injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: N-butyl-2-cyanoacrylate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lauromacrogol
Study: NCT03309072

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS
Description: active tDCS
Study: NCT01067274

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZACITIDINE (VIDAZA)
Description: 75 mg/m2/12h SC from D1 to D5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CYTARABINE
Description: Cytarabine : 60 mg/m2/12h SC from D1 to D5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CYTARABINE
Description: Cytarabine : 60 mg/m2/12h SC from D1 to D5
Study: NCT01333228

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Autologous bone marrow-derived endothelial progenitor cells
Description: Intraarterial administration (hepatic artery) of autologous bone marrow-derived endothelial progenitor cells
Study: NCT02109991

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CG-100 device
Description: Colorectal surgery performed per standard of care with deployment of the CG-100 device in the anastomosis site
Study: NCT04280055

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybin
Description: 0.14 mg/kg p.o. in three sessions spaced by one week
Study: NCT03309072

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham tDCS
Description: sham tDCS
Study: NCT01146340

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated radiotherapy
Description: 40 Gy / 5 fractions / 29 days
Study: NCT04139642

Intervention type: DEVICE
Intervention: SimpleSway
Description: During the 9-month period each practitioner who receives the balance + weight device is asked to provide anonymous feedback via a kiosk regarding if the balance data influenced clinical decision making after every patient. The kiosk has four marked buttons indicating a 4-point Likert Scale, so the practitioner just presses one of the four buttons to indicate their agreement with the statement, The balance measurement influenced my clinical decision making with this patient. After 9 months, the devices are switched so that every practitioner who had a weight only device receives balance + weight device and vice versa. After the second 9-month period concludes all devices will be retrieved by study personnel, and participants will be asked to complete surveys regarding their experience and attend group feedback sessions regarding their experiences.
Study: NCT02868411

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rectal Swab
Study: NCT03708718

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone 5 mg
Description: 5mg prednisolone, once a day for 6 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule; From August 2020 'no additional treatment'
Description: Matched placebo capsule, once a day for 6 months; From August 2020 - no additional treatment above standard of care medication
Study: NCT04681105

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diphenhydramine
Description: Given IV or PO

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Flotetuzumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranitidine
Description: Given IV
Study: NCT04110912

Intervention type: OTHER
Intervention: This is a registry and no interventions are taking place.

Intervention type: OTHER
Intervention: This is a registry and no interventions are taking place.

Intervention type: OTHER
Intervention: This is a registry and no interventions are taking place.

Intervention type: OTHER
Intervention: This is a registry and no interventions are taking place.
Study: NCT03010319

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PriMatrix Dermal Repair Scaffold
Description: Application of PriMatrix to ulcer

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Secondary Dressings
Description: Dressings to ensure moist wound environment

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Secondary Dressings
Description: Dressings to ensure moist wound environment

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Offloading device
Description: Offloading device to decrease pressure to wound area

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Offloading device
Description: Offloading device to decrease pressure to wound area
Study: NCT02366312

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vismodegib
Description: vismodegib is a synthetic, small molecule inhibitor of the sonic Hh pathway, which is involved in tumorigenesis, thus providing a strong rationale for its use in the treatment of a variety of cancers.
Study: NCT02532465

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Air-Q

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: i-gel
Study: NCT00824473

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.15% azelastine hydrochloride
Description: 0.15% azelastine hydrochloride 822 mcg
Study: NCT04222296

Intervention type: DEVICE
Group type: OTHER
Intervention: Fitting strategy of cohlear implant of hearing aid
Description: To determine whether new hardware and fitting strategy provides better sound quality or ease of use than generic hardware and fitting methods

Intervention type: DEVICE
Group type: OTHER
Intervention: Fitting strategy of cohlear implant of hearing aid
Description: To determine whether new hardware and fitting strategy provides better sound quality or ease of use than generic hardware and fitting methods

Intervention type: DEVICE
Group type: OTHER
Intervention: Fitting strategy of cohlear implant of hearing aid
Description: To determine whether new hardware and fitting strategy provides better sound quality or ease of use than generic hardware and fitting methods
Study: NCT03938896

Intervention type: OTHER
Group type: OTHER
Intervention: platelet rich plasma
Description: Patients were put in supine position. Betadine was used to disinfect the skin of the heel. 1 ml of local anesthesitic (lidocaine) was injected;then, by the same syringe, 2.5 ml of PRP was injected in the tenderestarea.After extraction of the needle, a bandage was puton the injected area. The patient was kept in the supine position for twentyminutes and then discharged

Intervention type: OTHER
Group type: OTHER
Intervention: corticosteroid
Description: Patients were put in the supine position. Injection was done usingthe medial technique. Identification of the tenderest point of the heel was done by palpation. Antiseptic solution was used to disinfect the skin overlying theheel. Then1ml of 40 mg methylprednisolone acetate and 1 ml of local anaesthetic as lidocaine 2% were injected into the plantar fascia by a 22gauge needle. After injection, participants were advised to stay sitting without foot movement for 15 minutes
Study: NCT00414141

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Grass MATA MPL
Description: 4 subcutaneous injections

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 4 subcutaneous injections
Study: NCT04100382

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laser and SLA
Description: Patients will be randomized into two groups, control group for SLA implants, and study group will receive the Laser treated implants. Implants will be placed classically in the posterior maxillary region and their stability will be measured by ISQ device at the placement. Measurements will be taken again at 2, 4, 6, 8 , 10 and 12 weeks.
Study: NCT04016909

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: aerobic exercise plus calorie restriction
Description: both a 6-month aerobic exercise program (moderate intensity) and caloric restriction (12.5% energy deficit)
Study: NCT04491474

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine Hydrochloride
Description: While performing these procedures, 1 ml of 2% lidocaine hydrochloride and 1 ml of %0.9 saline will be used for creating a solution of 2 ml of 1% lidocaine for nerve block. Also 2 ml of saline will be used for placebo effect. For blocking the GON region 0.75 ml of 1% lidocaine will be applied and 0.75 ml of saline for placebo effect(8). During applying to the SON region 0.25 ml of 1% lidocaine for blockage and 0.25 ml of saline for placebo effect will be used(8). The GON injection site was planned to be 2 cm lateral and 2 cm below the occipital protrusion and the SON injection site was planned as the area with frontal incisor in the orbital arch
Study: NCT01080807

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Armodafinil
Description: At the baseline visit, patients who continued to meet eligibility criteria were randomly assigned (1:1) to receive either 150 mg of armodafinil or matching placebo treatment only on nights worked for 6 weeks. Study drug was taken once nightly, 30 to 60 minutes prior to the start of the night shift, on nights worked. Armodafinil treatment was titrated as follows (only on nights worked): the first dose was 50 mg (1 tablet), the second and third doses were 100 mg (2 tablets), and the fourth and subsequent doses were 150 mg (3 tablets). Placebo tablets matching armodafinil tablets were administered on the same schedule.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo
Description: At the baseline visit, patients who continued to meet eligibility criteria were randomly assigned (1:1) to receive either 150 mg of armodafinil or matching placebo treatment only on nights worked for 6 weeks. Study drug was taken once nightly, 30 to 60 minutes prior to the start of the night shift, on nights worked. Armodafinil treatment was titrated as follows (only on nights worked): the first dose was 50 mg (1 tablet), the second and third doses were 100 mg (2 tablets), and the fourth and subsequent doses were 150 mg (3 tablets). Placebo tablets matching armodafinil tablets were administered on the same schedule.
Study: NCT02420093

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pelvis Support Assembly
Description: Use of a portable and adjustable Pelvis Support Assembly in the seat of the subject's work or home desk chairs as tolerated during the 3 weeks intervention interval. This pelvic support device supports the user from the pelvis and aids in maintaining a more anatomically neutral lumbar and pelvic position in sitting. This device is not officially named at this time but is as represented in US Patent number is US 8,857,906 B2.
Study: NCT04268108

Intervention type: BIOLOGICAL
Intervention: liquid tumor infiltrating lymphocytes
Description: Isolatation and amplification PD-1+ cells from peripheral blood lymphocytes under GMP conditions for clinical use.
Study: NCT02802566

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: BMI-based prenatal vitamin
Description: The intervention group receives additional antioxidant micronutrients that we have found to be decreased in obese pregnant women.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Standard prenatal vitamin
Description: Standard prenatal vitamin
Study: NCT01550757

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Embedded Peer Mentor
Description: This intervention/condition consists of a formerly homeless individual embedded in the PACT or H-PACT clinic team. This person is responsible for community-based follow-up for homeless patients randomly assigned to him or her. In addition to structured, scheduled meetings with assigned study subjects, the peer mentor will also participate in PACT/H-PACT team meetings and serve as a liaison between the study subject and his or her primary care team. Peer mentors will be hired as VA term employees in Research.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Embedded Peer Mentor
Description: This intervention/condition consists of a formerly homeless individual embedded in the PACT or H-PACT clinic team. This person is responsible for community-based follow-up for homeless patients randomly assigned to him or her. In addition to structured, scheduled meetings with assigned study subjects, the peer mentor will also participate in PACT/H-PACT team meetings and serve as a liaison between the study subject and his or her primary care team. Peer mentors will be hired as VA term employees in Research.
Study: NCT03560336

Intervention type: DRUG
Intervention: Liraglutide
Description: Patients will initiate treatment with liraglutide according to the approved label in Korea. Patients will initiate 0.6 mg daily and weekly increase the dose by 0.6 mg until reaching 3.0 mg daily. Patients will then continue to stay on 3.0 mg/day (total treatment duration: 26 weeks).
Study: NCT04491474

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine Hydrochloride
Description: While performing these procedures, 1 ml of 2% lidocaine hydrochloride and 1 ml of %0.9 saline will be used for creating a solution of 2 ml of 1% lidocaine for nerve block. Also 2 ml of saline will be used for placebo effect. For blocking the GON region 0.75 ml of 1% lidocaine will be applied and 0.75 ml of saline for placebo effect(8). During applying to the SON region 0.25 ml of 1% lidocaine for blockage and 0.25 ml of saline for placebo effect will be used(8). The GON injection site was planned to be 2 cm lateral and 2 cm below the occipital protrusion and the SON injection site was planned as the area with frontal incisor in the orbital arch

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine Hydrochloride
Description: While performing these procedures, 1 ml of 2% lidocaine hydrochloride and 1 ml of %0.9 saline will be used for creating a solution of 2 ml of 1% lidocaine for nerve block. Also 2 ml of saline will be used for placebo effect. For blocking the GON region 0.75 ml of 1% lidocaine will be applied and 0.75 ml of saline for placebo effect(8). During applying to the SON region 0.25 ml of 1% lidocaine for blockage and 0.25 ml of saline for placebo effect will be used(8). The GON injection site was planned to be 2 cm lateral and 2 cm below the occipital protrusion and the SON injection site was planned as the area with frontal incisor in the orbital arch

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Placebo
Description: There will be injection of %0.9 saline to bilaterally great occipital nerve and to bilaterally supraorbital nerve.
Study: NCT01939834

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Overnight CLC
Description: Overnight Closed-Loop Control (CLC) is run on the DiAs which is a medical platform that uses a smart-phone to connect to a continuous glucose sensor to insulin pump. The cell phone runs the CLC and is connected to work with the insulin pump and continuous glucose monitor to help keep the blood sugar in a desired range.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Overnight CLC
Description: Overnight Closed-Loop Control (CLC) is run on the DiAs which is a medical platform that uses a smart-phone to connect to a continuous glucose sensor to insulin pump. The cell phone runs the CLC and is connected to work with the insulin pump and continuous glucose monitor to help keep the blood sugar in a desired range.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sensor-Augmented Pump Therapy (SAP)
Description: The subject will be on their home insulin pump (UVA) or study pump (Italy) and using a CGM per their usual care.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sensor-Augmented Pump Therapy (SAP)
Description: The subject will be on their home insulin pump (UVA) or study pump (Italy) and using a CGM per their usual care.
Study: NCT01300741

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lotrafilcon B contact lens (AIR OPTIX® AQUA)
Description: Silicone hydrogel, single vision contact lens worn in one eye in a daily wear modality for approximately 5 days or more per week, at least 10 hours per day, for up to 4 weeks.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Galyfilcon A contact lens (ACUVUE® ADVANCE® Plus)
Description: Silicone hydrogel, single vision contact lens worn in one eye in a daily wear modality for approximately 5 days or more per week, at least 10 hours per day, for up to 4 weeks.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Contact lens solution (Clear Care®)
Description: Hydrogen peroxide-based system used for cleaning, disinfection and overnight storage of the study contact lenses.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Contact lens solution (Clear Care®)
Description: Hydrogen peroxide-based system used for cleaning, disinfection and overnight storage of the study contact lenses.
Study: NCT04275375

Intervention type: OTHER
Intervention: observation study about the autonomic response after spinal anesthesia
Description: ECG waveforms were continuously recorded using a multichannel polygraphic system (Embla N7000, Natus, Pleasanton, CA). The data were saved at a rate of 1024 Hz directly to a memory card within the device for offline analysis of heart rate variability (HRV) and PPG. All data included in the analysis were obtained from continuous artifact-free ECG recordings for analysis of the immediate effects of spinal anesthesia.
Study: NCT01822457

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nike FuelBand (NFB)
Description: The Nike Fuel Band (NFB) is a wrist-worn sensor with a built-in accelerometer for motion quantification. It is programmed to estimate the number of steps taken per day, and also predict energy expenditure in units known as Nike Fuel. Accompanying software allows the user to set daily targets and monitor their activity through a graphical user interface.
Study: NCT01809522

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Posterior reconstruction of the rhabdosphincter
Study: NCT01361646

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LC350189
Description: Single Ascending Dose: 10, 25, 50, 100, 200, 400, 600mg Multifle Ascending Dose: 100, 200, 400, 600, 800mg
Study: NCT01361646

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LC350189
Description: Single Ascending Dose: 10, 25, 50, 100, 200, 400, 600mg Multifle Ascending Dose: 100, 200, 400, 600, 800mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LC350189
Description: Single Ascending Dose: 10, 25, 50, 100, 200, 400, 600mg Multifle Ascending Dose: 100, 200, 400, 600, 800mg
Study: NCT01504022

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telecare, selfmonitoring, lifestyl behaviour
Description: Patients measure their own bloodpressure and the results are shown at a secured website after USB connection of the monitor to the computer. Patients receive medication adjustments and lifestyle advices via this secured website.
Study: NCT04198792

Intervention type: OTHER
Intervention: No intervention
Description: No intervention, but ECPR patients will be compared to ECMO-patients that have not had cardiac arrest

Intervention type: OTHER
Intervention: No intervention
Description: No intervention, but ECPR patients will be compared to ECMO-patients that have not had cardiac arrest
Study: NCT03321084

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MatPliates
Description: The MatPilates program was specialized developed for this trial, in which all exercises belong to contemporaneous Pilates style. Each session has 60 minutes of duration, divided in three blocs (stretching, exercise and relaxation), with mean of 10, 40 and 10 minutes respectively (VIEIRA et al., 2016). Each exercise will be performed in one series of 10 to 15 repetitions and will be modified accordingly the patient need.

Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: Will not be submitted to any physical intervention. It continues in your daily life with only phone monitoring.
Study: NCT00295191

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: high-flux membrane
Description: high-flux dialyser

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: low-flux membrane
Description: low-flux dialyser

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional dialysate
Description: conventional dialysate

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ultrapure dialysate
Description: ultrapure dialysate
Study: NCT03101254

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3022855
Description: LY3022855 is a colony-stimulating factor-1 receptor (CSF-1R) inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3022855
Description: LY3022855 is a colony-stimulating factor-1 receptor (CSF-1R) inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3022855
Description: LY3022855 is a colony-stimulating factor-1 receptor (CSF-1R) inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3022855
Description: LY3022855 is a colony-stimulating factor-1 receptor (CSF-1R) inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vemurafenib
Description: Vemurafenib is a BRAF inhibitor that works by blocking altered BRAF proteins from stimulating the growth of melanoma cancer cells

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vemurafenib
Description: Vemurafenib is a BRAF inhibitor that works by blocking altered BRAF proteins from stimulating the growth of melanoma cancer cells

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vemurafenib
Description: Vemurafenib is a BRAF inhibitor that works by blocking altered BRAF proteins from stimulating the growth of melanoma cancer cells

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vemurafenib
Description: Vemurafenib is a BRAF inhibitor that works by blocking altered BRAF proteins from stimulating the growth of melanoma cancer cells

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobimetinib
Description: Cobimetinib works by blocking a protein called MEK that has been known to promote melanoma growth

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobimetinib
Description: Cobimetinib works by blocking a protein called MEK that has been known to promote melanoma growth

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobimetinib
Description: Cobimetinib works by blocking a protein called MEK that has been known to promote melanoma growth

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobimetinib
Description: Cobimetinib works by blocking a protein called MEK that has been known to promote melanoma growth
Study: NCT03170661

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deep neuromuscular block
Description: Deep neuromuscular block will be achieved with high dose rocuronium to achieve a depth of 1-2 twitches post tetanic count